Chi's Enterprise Myomin, 120 caps
Aromatase Inhibitor for Estrogen-Dominant Disorders
Myomin benefits women with high levels of estrogen or experiencing symptoms caused by high estrogen levels. Myomin benefits women experiencing symptoms caused by uterine fibroids, cysts, endometriosis, and estrogen-receptive growths.
Yes! Myomin benefits men who are experiencing high levels of estrogen. Men get high levels of circulating estrogens from environmental toxins, just like women, or from poor liver detoxification, obesity or other reasons.
Myomin has shown to benefit men with specific prostate disorders. As men age, testosterone decreases and estrogen increases. Given that Myomin helps minimize estrogen formation, this indirectly increases testosterone.
Myomin Side Effects
Myomin side effects are minimal and the side effects by Myomin can be avoided:
Chang Hai Hospital studies show approximately 1% of the subjects taking Myomin experienced side effects such as nausea and bloating. These Myomin side effects typically go away when the Myomin dosage is reduced or when Myomin is taken with meals.
- Note: Try Myomin Plus for added GI comfort if reducing dosage of Myomin does not alleviate side effects of Myomin.
Estrogen-dominant disorders such as endometriosis, cysts, fibroids and cellular mutations may benefit from taking Myomin by Dr Chi.
Myomin supports the reduction of estrogen production which is why Myomin is so effective for many women in reducing uterine fibroids and reducing estrogen-sensitive cells.
Myomin is an all-natural herbal formula that can support the reduction of estrogen through Chinese herbs.The herbal ingredients of Myomin are Aralia, Smilax glabra, Curcurma zedoria, and Cyperus otundus. These herbs have been traditionally used for various female ailments and hormone related disorders. Aralia and Cyperus rotundus both help reduce estradiol. Cyperus is also effective against cervical endometriosis and cervical carcinoma.
Aromatase is a key enzyme in the synthesis of estrogen. Specifically, it converts androstenedione into estrone and testosterone into estradiol. For instance, evidence shows that genetic mutations that occur in the breast and prostate tissues overexpress aromatase. Inhibiting aromatase, therefore, plays an important role in suppressing the deleterious action of estrogen on hormone related conditions. This is why Myomin is so helpful in uterine fibroids and other high estrogen disorders such as endometriosis.
An in vivo study demonstrated that Myomin inhibits the aromatase enzyme in the ectopic endometrium and ovarian tissue of rats. Aromatase was expressed markedly in the untreated ectopic endometrium of the positive control group. On the other hand, aromatase expression significantly decreased in the ectopicendometrium of the Myomin group after 28 days.
Myomin has three functions:
- Myomin inhibits the aromatase enzyme, effectively reducing estradiol levels by preventing the conversion of androgens to estrone and estradiol. This allows testosterone and estriol (the good estrogen) to accumulate. Aromatase inhibition has become a worthwhile target in many estrogen-dominant disorders
- Myomin competes with estradiol at the estrogen receptors. This function is particularly effective in cases where estrogen receptors are fully stimulated (e.g. after HRT). Competing with estradiol prevents estradiol from binding to receptors. As a result, proliferation of cells is avoided and abnormal growth inhibited.
- Myomin increases interferon (IFN) and interleukin-2 (IL-2). IL-2 induces the proliferation of immune cells, enhancing the body's ability to eradicate abnormal cells. IFN stimulates natural killer cells that are active against these neoplasmatic cells.
Myomin Reduces Estradiol Levels
One study performed at the Shanghai Medical School illustrates the effect of Myomin on estradiol levels of mice during pregnancy – a period when estradiol levels are especially high. Two groups of 12 mice each were used in the study. One group was used as the control. The other group was given Myomin beginning 15 days into pregnancy. Three days later (on the 18 th day of the study), the average estradiol level of the Myomin group was 7.22pg/ml, approximately seven times less than the control group. After 6 days of taking Myomin (on the 21 st day of the study), their average estradiol level was 8.81pg/ml while it was 85.98 pg/ml for the control group.
In another study, 90 female mice were divided into three groups. Each group was then given Myomin for 30, 60 and 180 days, respectively. The average estradiol levels after each period was 50.6, 36.6, and 32.4 pg/ml, respectively. After 180 days, the estradiol level stabilized. These results demonstrate long-term use of Myomin reduces estradiol in such a way that it maintains around the normal level. No side effects were reported in this study.
A human study involved 60 postmenopausal women with cysts and/ or fibroids. Postmenopausal women were studied because their estradiol levels are more stable than those of premenopausal women. Initially, the average estradiol level was 74.52 pg/ml. After only 10 days on Myomin, their average estradiol level reduced to 38.84 pg/ml. The fibroids, cysts and associated pain gradually reduced.
Myomin and Estrogen Dominant Disorders
A study from Chang Hai Hospital involved 75 cases of fibrocystic breasts (70 women ages 18 to 52 years old and 5 men ages 62 to 64 years old). Sixty five percent of the women were under 35 years old. 25 cases were in the control group while 50 cases were in the Myomin group. Results of the study revealed that, in 14 cases, the fibrocystic breast completely cleared after 1 month of taking Myomin while, in 16 cases, the fibrocystic breast reduced 50% in size. Among the five men in the study, the cysts cleared completely in 3 cases. Overall, the effectiveness rate of Myomin is more than 60%, compared to the control group's 12% rate. In the Myomin group, in 48 out of 50 cases,associated pain cleared or tremendously reduced (p value <0.05) while in the control group, pain reduced in only 12 out of 25 cases.
A 1994 clinical study was conducted on 255 patients with ovarian cysts and endometriosis. After 5 months, Myomin was effective on 147 patients (57%) while some improvements was observed in 87 patients (34.1%). No effect was observed in only 21 patients.
Another study was conducted on both pre- and postmenopausal women with ovarian cysts. In one study from the Chang Hai Hospital in Shanghai, China, 85 female patients with ovarian cysts were involved, with ages ranging from 27to 64 years old (more than 50% of them between 34 and 45 years old). Out of the 85, 40 cases were related to endometriosis (hyatidiform cyst), 44 cases were simple ovarian cysts. After 1 to 3 courses of the herbal formula, the cysts and symptoms of 15 patients completely cleared with no recurrence 3 months after the study. In 34 patients, the size of the cyst reduced by 50% and some of the associated symptoms were relieved.
The potential applications of aromatase inhibitors in many health conditions are continually increasing. However, the aromatase inhibitor drugs in the market today are indicated for postmenopausal women only. This is very limiting especially since more and more premenopausal women are developing estrogen-related conditions. It is for this reason that the results of these studies on Myomin are significant. As stated before, Myomin has been used in clinical studies and found to be effective in both premenopausal and postmenopausal women with ovarian cysts, fibrocystic breast and endometriosis as well as in men with fibrocystic breast. It is able to produce these favourable results by inhibiting aromatase and consequently reducing estrogen levels.
Myomin and Men: More Information:
Aromatase inhibition is important in men as well. As men age, testosterone is being more readily converted to estrogen through the aromatase enzyme. Increased estrogen levels have been linked to prostate problems. Evidence suggests that local aromatase expression in the prostate increases malignancy. In fact, the level of aromatase expression in malignant prostate tissue is comparable to that in malignant breast tissue. As a result, local estrogen levels are also promoted at the site of abnormal tissue growth in the prostate, increasing growth. Aromatase inhibitors like Myomin help block the action of aromatase, thereby minimizing the depletion of testosterone and reducing estrogen levels.
Myomin for Relief of Menopausal Symptoms
Myomin has also been reported to be effective in reducing the severity and frequency of hot flashes in some women. Although its exact mechanism on this particular function remains to be elucidated, it may be explained by Myomin's ability to compete with estrogen at the cells' estrogen receptors. It should be noted, however, that some women experience worsening of symptoms with Myomin. This is probably due to very low levels of estrogen in these women.
Myomin for Abdominal Fat
An aromatase inhibitor like Myomin may also affect abdominal fat. Abdominal obesity is associated with decreased testosterone levels (or hypogonadism) and increased estradiol levels. Hypogonadism leads to the deposition of fat in the abdomen. As fat accumulates, aromatase activity increases at the site, causing more testosterone to be converted into estradiol. Taking testosterone or DHEA supplements is not enough because if aromatase is uncontrolled, then testosterone and DHEA will eventually be converted to estradiol. Adding anaromatase inhibitor like Myomin blocks the action of aromatase, preventing the testosterone from being converted into estradiol.
Myomin for Osteoporosis and Kidney Function
Myomin has also been shown to be excellent in the improvement of osteoporosis and kidney function. In a test including 160 people (152 women and 8 men) with osteoporosis, 29% of the patients actually improved their condition with use of the product, as well as their overall bone density in a course of 2 years. Conventional calcium treatment methods showed only a 10% rate of effectiveness. And since the product is shown to be good for the kidneys, it works to prevent hair loss in those with poor kidney function. In tests conducted on over 1000 patients at the Bejing Red Cross Hospital, 86% benefited from Myomin use.